INTERCEPT Platelets
Approval of the INTERCEPT Blood System for platelets in 2002 represented a significant advancement in blood safety. For the first time, bacterial contamination risks unique to platelets due to their room temperature storage could be proactively mitigated while simultaneously providing protection from a wide variety of viruses, protozoa, and leukocytes.
Proven in routine use More than 500,000 INTERCEPT treated platelet concentrates have been transfused to date. The technology is in routine use in over 80 blood centers throughout Europe and the Middle East. An extensive hemovigilence program has documented the transfusion outcomes for more than 32,000 platelet components.
Reduced transfusion reactions reported Two routine INTERCEPT users have reported detailed data comparing the rates of transfusion reactions pre and post INTERCEPT implementation. Results from both centers indicate a significant reduction in transfusion reactions after the adoption of INTERCEPT. 1,2
Economics that make sense The INTERCEPT system is compatible with double dose platelet collections allowing blood centers to produce two therapeutic platelet units from a single INTERCEPT treatment with the dual storage set.
INTERCEPT is also approved as an alternate to gamma irradiation for the prevention of transfusion associated graft versus host disease (TA-GvHD) allowing INTERCEPT users to eliminate gamma irradiation of their platelet components while providing the greatest available protection against transfusion transmitted diseases.
Release at the same time and store up to 7 days The flexible treatment process does not impact platelet release time and is compatible with up to 7 day storage according to local requirements
|
